Webinar
To freeze or not to freeze - challenges and innovations in cell therapy logistics
On-demand
In recent years, Advanced Therapy Medicinal Products (ATMPs) have evolved into a promising and highly hoped-for medical approach to cure a broad spectrum of diseases, ranging from cancer to immunological disorders and rare diseases.
From development, collection, manufacturing, and infusion back into the patient, the journey of a cell therapy requires intricate logistics to maintain product integrity and patient safety. Challenges and requirements can vary according to the specific type of therapy, and a deep understanding of the end-to-end workflow is critical.
Following harvest from the patient, cells can either be shipped fresh (2ºc to 8ºc) or cryopreserved and stored for later use.
Join experts from Albumedix, Cytiva, Miltenyi Biomedicine, and World Courier to learn more about:
- The logistics challenges and solutions for fresh or frozen cell shipments and the reasons to choose one approach over the other
- How to extend the shelf life of cells
- Innovations in shipping and storage
Don’t miss this opportunity to ask your questions live and hear from accomplished specialists about how logistics and distribution play a critical role in the success of these breakthrough therapies.
Andrea Zobel
Andrea leads the Cell and Gene Therapy and Direct-to-Patient service lines at World Courier, with a focus on defining strategy, driving growth and solving operational and process challenges which arise from the complexity of these shipments.
With a wealth of expertise and experience gained across academia, pharmaceutical services and clinical trials logistics, Andrea has served in a number of senior leadership roles in research and development, clinical trial supply chain as well as product and project management before joining World Courier in 2021.
In parallel, Andrea is an active member of the ISPE (International Society for Pharmaceutical Engineering), author for the PDA (Parentarel Drug Association), HBA (Healthcare Business Women Association) and the female manager network of the VBU (Verband der Biotechnologieunternehmen).
Bill Shingleton
Passionate about delivering Advanced Therapeutic Medicinal Products (ATMPs) to patients.
Focussed on developing technology that will enable successful translation and commercialisation.
Biological Scientist, with a background in inflammation, biology of ageing and connective tissues. Applying this research in the fields of auto-immune, degenerative diseases and oncology.
Experience gained in academia at the Universities of Cambridge and Newcastle-upon-Tyne, combined with over 15 years of industrial research with Unilever R&D, GE Healthcare Life Sciences and now Cytiva.
Recent roles have been supporting the Cell Therapy Industry through and the application of in-vivo imaging to enable safety, efficacy and MoA studies, and development of tools and technology for cell therapy manufacturing and cryo-preservation.
Current role is focussed on Leading a global team of biologists and engineers developing technology to enable the development of equipment, consumables, software and processes for the manufacture of cell and gene therapies.
Michael Terhoeven
Michael Terhoeven joined Miltenyi Biomedicine in 2020 and is responsible for implementing the Supply Chain Strategy, leading the CAR-T cell logistics and the contracting for our manufacturing globally.
Michael joined the company from DHL, where he had long long-standing career of 16 years with multiple strategic roles including life science logistics, cold chain and environment monitoring.
Prior to DHL, he worked with a pre-clinical biotech start-up in Berlin and for 7 years with the Boston Consulting Group.
Michael holds a Doctor of Natural Sciences (Dr. rer. Nat.) in Mathematical Physics from the University of Bonn
Phil Morton
Dr. Philip Morton has a strong technology background with over 25 years’ experience in the biopharmaceutical industry within process and product development, initially in the development of downstream processes followed by an interest in the characterisation of products and their impurity profiles.
Latterly he has been involved in product application research with both an internal and external focus. He was trained as a biochemical engineer and has biopharmaceutical experience in both R&D and manufacturing environments in Albumedix under its former owners of Delta Biotechnology, Aventis and Novozymes.
He currently heads up the Technology group for Albumedix looking after all aspects of Biotechnology Innovation within the company.